(Press-News.org) Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research.
The findings from the Phase III trial are presented today at the European Association of Urology congress (EAU21).
There is a high risk of kidney cancer returning, following surgery to remove tumours, but there is currently no treatment to help prevent this.
The KEYNOTE study involved just under 1000 patients with kidney cancer who had undergone surgery. Half of them were given the immunotherapy drug pembrolizumab, or pembro, and the other half a placebo.
Pembro is used to treat a number of cancers, including late-stage kidney cancer, where the disease has spread to other organs. The international trial across 20 countries was the first time the drug had been used with patients at an early stage of the disease.
The team found that over two years, patients on pembro were a third less likely to see their disease return than those on the placebo. Follow-up with patients is continuing, to determine the impact of the treatment on survival rates over a five-year period.
The study also showed that the side effects from the drug were similar to those normally expected with a cancer treatment.
Co-investigator on the study, Professor Thomas Powles of Barts Cancer Institute at Queen Mary University of London, said: "This early data from the trial is very promising, with a clear reduction in the disease recurring in patients on pembro. There are signs as well that the drug may improve survival rates, but we can't be sure of that for another few years. We're hopeful that this trial, when complete, will provide a strong case for this drug to be approved for use by the medicines regulator."
Combination immunotherapy promising for advanced bladder cancer
Professor Powles is presenting further findings at EAU21 today from another trial, which also involves a new use for an existing cancer immunotherapy drug. The DANUBE study looked at durvalumab in patients with late-stage bladder cancer, where the disease had already spread to other parts of the body. Durvalumab is used widely as a lung cancer treatment, particularly in the USA.
Over 1000 patients were recruited to the trial, with a third of them receiving durvalumab, a third receiving durvalumab combined with a new immunotherapy drug, tremelimumab, and a third receiving standard chemotherapy.
They found that overall, the immunotherapy drugs did not increase survival more than standard chemotherapy.
However, in exploratory analysis, in a subset of patients (those who had a raised level of a specific biomarker (PD-L1) and who weren't eligible for the chemotherapy drug cisplatin) the activity of durvalumab was increased by the addition of tremilimumab.
Professor Powles said: "While we weren't comparing durvalumab against other licensed immune therapies in this clinical situation, we could see the new combination of immunotherapies did show some additional promise that warranted a more detailed look."
Two large randomised controlled trials are now underway, testing durvalumab and tremelimumab against the existing immunotherapy treatments, both in late-stage and early-stage bladder cancer, in patients with high levels of the LD-P1 biomarker who can't be given cisplatin. The results from the first trial should be reported later this year, while the other is still recruiting.
INFORMATION:
Researchers in Belgium report on the case of a 90-year-old woman who was simultaneously infected with two different variants of concern (VOCs) of COVID-19, in a Case Report being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
On March 3 2021, the woman, whose medical history was unremarkable, was admitted to the OLV Hospital in the Belgian city of Aalst after a spate of falls. She tested positive for COVID-19 on the same day. She lived alone and received nursing care at home, and had not been vaccinated against COVID-19.
Initially, there were no ...
New research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held online this year, reveals raw dog food to be a major source of antibiotic-resistant bacteria, making it an international public health risk.
With some of the multidrug-resistant bacteria in raw dog food identical to those found in hospital patients in several different European countries, the researchers say the trend for feeding dogs raw food may be fuelling the spread of antibiotic resistant-bacteria.
Drug-resistant infections kill an estimated 700,000 people a year globally and, with the figure projected to rise to 10 million ...
The dangerous mcr-1 gene, which provides resistance to the last-resort antibiotic colistin, has been found in four healthy humans and two pet dogs. In two cases, both dog and owner were harbouring the gene, according to new research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
Since first being reported in China in 2015, the mcr-1 gene has been found in various people and animals around the world. It confers resistance to colistin, an antibiotic of last resort used to treat infections from some bacteria resistant to all other antibiotics. The nightmare scenario that could emerge is mcr-1 combining with already drug-resistant bacteria ...
Nashville, Tenn. (3:24 p.m. EDT--July 10, 2021)--Approximately 12 percent of patients who underwent shoulder stabilization surgery experience arthritis in the shoulder joint within a seven-year period, according to research presented today at the American Orthopedic Society for Sports Medicine-Arthroscopy Association of North America Combined 2021 Annual Meeting.
"While arthroscopic stabilization for posterior glenohumeral instability has shown excellent success preventing recurrent instability and allowing return to sport, eventual progression to glenohumeral arthritis ...
Nashville, Tenn. (July 10 2021--2:25 EDT)--Patients undergoing hip arthroscopy with high-grade cartilage damage do not see as positive results compared with patients with lower grade cartilage damage, according to research reported today at the American Orthopedic Society of Sports Medicine- Arthroscopy Association of North America Combined 2021 Annual Meeting.
The research was presented by Dominic Carreira, MD, of Peachtree Orthopedics in Atlanta, Ga. Dr. Carreira and his colleagues sought to determine what the impact of acetabular cartilage damage on outcomes following primary repair of acetabular labral tears.
When articular cartilage is damaged, joint ...
Nashville, Tenn. (1:35 p.m. EDT--July 10, 2021) -- Use of a biodegradable balloon spacer during massive rotator cuff tear surgery produced similar outcomes when compared to partial rotator cuff repair for patients with massive rotator cuff tears (MRCTs) at 24-month follow up, with potential for early improvement, according to research presented today at the American Orthopedic Society of Sports Medicine - Arthroscopy Association of North America Combined 2021 Annual Meeting.
Despite various treatment options, the successful management of irreparable, MRCTs remains challenging. Implantation of a biodegradable subacromial balloon spacer has gained considerable interest for the treatment of MCRTs due to its potential to recenter the humeral ...
"Topological defects" are formed when the symmetry of a magnetic material is disrupted. Domain walls (DWs) are a type of topological defect that separates regions of different magnetic orientations. A widely studied phenomenon, the manipulation of these defects has potential applications in high-performance memory storage devices, energy processing devices, and quantum computing.
Recently, the possibility of other topological defects embedded in or combined with DWs has gained attention for their potential applications in different fields of physics. Some examples of these "defects within defects" ...
Supplementing testosterone significantly reduces heart attacks and strokes in men with unnaturally low levels of the hormone, according to new research presented at the European Association of Urology congress today.
The ten-year study involved over 800 men from Germany and Qatar with testosterone deficiency, whose family history, blood pressure, cholesterol levels, diabetes or weight put them at high risk of heart attack or stroke.
Only men with testosterone levels below normal, who also displayed symptoms of low testosterone, such as low mood, decreased appetite, depression, erectile dysfunction, loss of libido or weight gain, were included in the research.
Just ...
Outpatient antibiotic prescribing fell by almost 4% a year between 2011 and 2018, according to a study of prescribing patterns in the largest integrated health care system in the USA, being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
Veterans Affairs (VA) facilities play a large role in the provision of outpatient care across the USA, providing care to over 9 million Veterans at more than 1,200 outpatient clinics.
The researchers speculate that the downward trend may be related to the antibiotic stewardship programmes widely implemented across the Veterans ...
New research presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) taking place online (9-12 July), suggests that three commonly prescribed classes of drugs that are not themselves antibiotics--proton pump inhibitors (PPIs), beta-blockers and antimetabolites--could lead to antibiotic resistant infections caused by bacteria from the Enterobacteriaceae family. These antibiotic resistant infections are in turn linked to longer hospital stays and potentially greater risk of death.
The observational study underscores the importance of commonly used non-antimicrobial drugs (NAMDs) as a risk factor for antibiotic resistance, researchers say.
Bacteria are thought to develop antibiotic resistance largely due to repeated exposure through over-prescribing, ...
